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Introduction
Infections caused by multi-drug resistant (MDR) Gram-
negative (GN) organisms in critically ill patients are a
therapeutic challenge. Few therapeutical options are
available.
Objectives
The administration of high-dose aminoglycoside (HDA)
therapy coupled with high-flow continuous veno-venous
hemodiafiltration (CVVHDF) could allow required high
drug peaks to be achieved with reduced toxicity.
Methods
All adult patients present on the intensive care unit
(ICU) between October 2009 and July 2014 who had
MDR-GN sepsis were considered for HDA and high-
flow (>45 mL/kg/h) CVVHDF when an isolated patho-
gen was at least partially sensitive to aminoglycosides
and the patient’s condition was not improving with
conventional therapy. Optimal antibacterial activity
was defined as a peak concentration of at least 8 times
the minimal inhibitory concentration.
Results
Fifteen patients infected with MDR-GN pathogens (11
with Pseudomonas aeruginosa; 10 with abdominal and 5
with respiratory infections) were treated with amikacin
(n = 11), gentamicin (n = 3) or tobramycin (n = 1) and
high-flow CVVHDF. A favorable clinical response was
observed in 8 (53%) patients, including 3 in whom micro-
bial eradication was obtained. Six patients were
discharged alive from the ICU, and five from the hospital.
No renal toxicity was observed.
Conclusions
In this cohort of septic patients with MDR-GN infec-
tions, HDA combined with high-flow CVVHDF repre-
sented a valuable therapeutic option. The effectiveness
of this approach should be further evaluated in larger
studies.
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